Laurent Duvernay-Tardif (born February 11, 1991) is a Canadian medical graduate and football guard for the Kansas City Chiefs of the National Football League (NFL). He was drafted by the Chiefs in the sixth round of the 2014 NFL Draft. He played college football at McGill University in Montreal, Quebec, Canada.
Offensive lineman Laurent Duvernay-Tardif enters his sixth
NFL season with Kansas City Chiefs without knee pain.
Montreal, Quebec (November 14, 2019) Emovi, Inc., today announced that it has signed a multiyear endorsement agreement with Kansas City Chiefs guard Laurent Duvernay-Tardif, to help support knowledge transfer to healthcare professionals and patients about Knee Kinesiography with KneeKG.
Duvernay-Tardif is one of the NFL’s best right guards and a graduate of Canada’s McGill University medical school. He is the only active NFL player who is also a medical doctor.
In 2017, Duvernay-Tardif suffered a left knee injury while playing football for the Kansas City Chiefs. An MRI confirmed his field diagnosis, which was a medial collateral ligament (MCL) sprain. He was back on the field after four weeks. In 2018, he fractured his fibula with the involvement of ankle ligaments and was back in the game after 16 weeks. Although his rehab process included physical therapy sessions, different orthotics, and a year of mechanical interventions, he continued to feel knee pain for almost two years. In 2019, Duvernay-Tardif was introduced to Emovi and had a Knee Kinesiography with the KneeKG.
Duvernay-Tardif’s Knee Kinesiography identified biomechanical markers that were a functional consequence of his injuries. The mechanical deficits identified included knee flexion, propulsive muscles, tibial rotation, hamstring versus quadricep absorption period, alignment in movement, and load and rotation – all which not only impair performance but also lead to higher injury risks. The assessment then guided a more specific rehabilitation and training program during his offseason to achieve complete pain-free functionality and optimal performance.
“With the results of the Knee Kinesiography, I integrated the recommended specific therapeutic plan to my training program,” said Duvernay-Tardif. ‘It has been very effective, and I’m back on the field without knee pain!”
“Every year the NFL releases a summary of the previous season’s injuries and knee injuries have topped the list every year since 2000. Like many other players in the NFL, I was part of that statistic without a solution to fully eradicate my pain. When I learned about the innovative approach provided by KneeKG and its ability to provide an accurate assessment of a knee in 3D while moving and weight-bearing, I was immediately intrigued. I wanted that test,” said Duvernay-Tardif.
KneeKG is the first in-clinic device that enables healthcare professionals to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. In contrast to the information provided by X-ray and magnetic resonance imaging (MRI) while the patient is in a static position, the KneeKG quickly identifies the functional motion and deficits of impaired knee(s). Like an EKG is for the heart, the Knee Kinesiography produced by the KneeKG provides valuable data that enables the physician and other healthcare professionals to determine the most appropriate patient-specific care to restore optimal knee function.
“The number of knee injuries that players in the NFL sustain is staggering, and the need for innovation was imminent. We are thrilled that our device helped get Laurent playing without knee pain,” said Michelle Laflamme, CEO Emovi. “We recognize and have great respect for Laurent’s achievements both as a professional athlete and a physician. We greatly appreciate his support and are honored to collaborate with him and his agent. They are a great team!”
About Emovi Inc. www.emovi.ca
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore patient quality of life. In partnership with the Quebec university research community, including the CRCHUM, École de technologie supérieure (ÉTS) and TELUQ. Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive worldwide license to commercialize the KneeKG.